Review of studies on SARS-CoV-2 infection inhibitors

Ann Agric Environ Med. 2021 Dec 29;28(4):541-550. doi: 10.26444/aaem/143035. Epub 2021 Oct 22.

Abstract

Introduction and objective: COVID-19 is a human infectious disease manifested by acute respiratory syndrome. On 30 January, 2020, the Word Heath Organization (WHO) declared a COVID-19 pandemic. The purpose of this article is to review publications on the search for substances that show inhibitory activity against SARS-CoV-2 infectivity, paying particular attention to the effect on different stages of the life cycle of the virus.

Review methods: The review was based on an analysis of the latest available scientific literature and international databases. The data collected relate to the years 2020-2021.

Brief description of the state of knowledge: Extremely intensive research is underway to find compounds that inhibit infection with the SARS-CoV-2 virus. Promising areas of research among the many current endeavours are antiviral compounds that stimulate the immune system, counter proliferation or affect individual viral replication cycles. These include, among others, interferons, monoclonal antibodies, natural compounds, peptides, aptamers, metal salts, and anti-inflammatory agents, inhibitors of viral enzymem, such as the RNA-dependent RNA polymerase. Preparations that help the body to combat the effects of infection have also assumed much importance.

Conclusions: The ongoing research is focused on the development of new antiviral agents, as well as the use of the existing drugs on the market. The results of clinical trials are promising and give hope for the development of effective therapies against SARS-CoV-2 and emerging variants of this virus.

Keywords: COVID-19; SARS-CoV-2; anti-inflammatories; antivirals.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • COVID-19*
  • Humans
  • Pandemics
  • SARS-CoV-2

Substances

  • Antiviral Agents